The Role of Adjuvant Radiotherapy in Management of Recurrent Pleomorphic Adenoma of the Parotid Gland: a Systematic Review

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 2018 Nov 15

PMID 30426229

Citations 7

Authors

Laura Mc Loughlin

Sarah Louise Gillanders

Susan Smith

Orla Young

Affiliations

Soon will be listed here.

Abstract

Purpose: Recurrent pleomorphic adenoma poses a significant treatment challenge, considering its propensity for further recurrence and potential for malignant transformation. The role of adjuvant radiotherapy in its management is widely debated. The aim of this study was to determine whether adjuvant radiotherapy is more effective than surgical resection alone in patients with recurrent pleomorphic adenoma of the parotid gland, in terms of further recurrence, malignant transformation and treatment-related complications.

Methods: Using PRISMA guidelines, a systematic review comparing adjuvant radiotherapy with surgery alone in the treatment of recurrent pleomorphic adenoma was conducted. Pubmed, OVID, EBSCO, Embase, The Cochrane Library, SCOPUS and OpenGrey databases from 1988 to 2018 were searched. Quality analysis was carried out using the Newcastle-Ottawa Scale and narrative synthesis used to summarise results.

Results: Of 891 records screened, eight studies were included, assessing 366 participants. Two noted a benefit of adjuvant radiotherapy in reducing further recurrence. The remainder did not show significant benefit, although four showed a trend towards lower rates. Only one case of malignant transformation was identified in a patient not irradiated. Similar rates of facial nerve dysfunction were identified between groups.

Conclusion: The available evidence suggests that adjuvant radiotherapy reduces recurrence rates in patients with recurrent pleomorphic adenoma and certain adverse prognostic factors. While it appears not to have significant adverse effects, given the lack of prospective evidence, we recommend careful use in patients at high risk of further recurrence and further research in the form of well-designed randomised controlled trials.

Citing Articles

Pleomorphic Adenoma - A Case Report on an Abnormal Mass.

Deenadayalan N, Pandyan D, Satheesh C, Aparnaa M, Harthi G Ann Maxillofac Surg. 2024; 14(1):89-92.

PMID: 39184409 PMC: 11340847. DOI: 10.4103/ams.ams_206_23.

"Unraveling the Tapestry": A Retrospective Exploration of Recurrent Parotid Pleomorphic Adenoma Cases.

Sundarajan K, Subagar A, Arumugam K Indian J Otolaryngol Head Neck Surg. 2024; 76(4):3227-3233.

PMID: 39130327 PMC: 11306486. DOI: 10.1007/s12070-024-04650-7.

Pleomorphic Adenoma of a Minor Salivary Gland of the Hard Palate: A Case Report.

Panchal I, Wanjari A Cureus. 2023; 15(10):e47957.

PMID: 38034256 PMC: 10685388. DOI: 10.7759/cureus.47957.

Treatment of relapses of benign latero-cervical pathology: a narrative literature review.

Meliante P, Colizza A, Ralli M, Minni A, Angeletti D, Cambria F Acta Otorhinolaryngol Ital. 2023; 43(Suppl 1):S76-S83.

PMID: 37698104 PMC: 10159646. DOI: 10.14639/0392-100X-suppl.1-43-2023-10.

The Importance of Prostate-Specific Membrane Antigen Expression in Salivary Gland Tumors.

Sivrice M, Yasan H, Kumbul Y, Ertunc O, Sayin S Turk Arch Otorhinolaryngol. 2023; 60(4):206-211.

PMID: 37456601 PMC: 10339265. DOI: 10.4274/tao.2022.2022-12-3.

References

Dawson A . Radiation therapy in recurrent pleomorphic adenoma of the parotid. Int J Radiat Oncol Biol Phys. 1989; 16(3):819-21. DOI: 10.1016/0360-3016(89)90501-4. View

Redaelli de Zinis L, Piccioni M, Antonelli A, Nicolai P . Management and prognostic factors of recurrent pleomorphic adenoma of the parotid gland: personal experience and review of the literature. Eur Arch Otorhinolaryngol. 2007; 265(4):447-52. PMC: 2254466. DOI: 10.1007/s00405-007-0502-y. View

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g7647. DOI: 10.1136/bmj.g7647. View

Sood S, McGurk M, Vaz F . Management of Salivary Gland Tumours: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130(S2):S142-S149. PMC: 4873929. DOI: 10.1017/S0022215116000566. View

Malard O, Wagner R, Joubert M, Delemazure A, Rio E, Durand N . Prognostic factors for secondary recurrence of pleomorphic adenoma: a 20-year, retrospective study. J Laryngol Otol. 2013; 127(9):902-7. DOI: 10.1017/S0022215113001801. View

Colella G, Cannavale R, Chiodini P . Meta-analysis of surgical approaches to the treatment of parotid pleomorphic adenomas and recurrence rates. J Craniomaxillofac Surg. 2015; 43(6):738-45. DOI: 10.1016/j.jcms.2015.03.017. View

Bailey H . Parotidectomy: indications and results. Br Med J. 2010; 1(4499):404-7. PMC: 2052784. DOI: 10.1136/bmj.1.4499.404. View

Sale K, Wallace D, Girod D, Tsue T . Radiation-induced malignancy of the head and neck. Otolaryngol Head Neck Surg. 2004; 131(5):643-5. DOI: 10.1016/j.otohns.2004.05.012. View

Witt R, Eisele D, Morton R, Nicolai P, Vander Poorten V, Zbaren P . Etiology and management of recurrent parotid pleomorphic adenoma. Laryngoscope. 2014; 125(4):888-93. DOI: 10.1002/lary.24964. View

10.

Abu-Ghanem Y, Mizrachi A, Popovtzer A, Abu-Ghanem N, Feinmesser R . Recurrent pleomorphic adenoma of the parotid gland: Institutional experience and review of the literature. J Surg Oncol. 2016; 114(6):714-718. DOI: 10.1002/jso.24392. View

11.

Radfar L, Sirois D . Structural and functional injury in minipig salivary glands following fractionated exposure to 70 Gy of ionizing radiation: an animal model for human radiation-induced salivary gland injury. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003; 96(3):267-74. DOI: 10.1016/s1079-2104(03)00369-x. View

12.

Ravasz L, Terhaard C, Hordijk G . Radiotherapy in epithelial tumors of the parotid gland: case presentation and literature review. Int J Radiat Oncol Biol Phys. 1990; 19(1):55-9. DOI: 10.1016/0360-3016(90)90134-6. View

13.

Miyahara H, Sato T, Yoshino K . Radiation-induced cancers of the head and neck region. Acta Otolaryngol Suppl. 1998; 533:60-4. DOI: 10.1080/00016489850183773. View

14.

van der Laan B, Baris G, Gregor R, Hilgers F, Balm A . Radiation-induced tumours of the head and neck. J Laryngol Otol. 1995; 109(4):346-9. DOI: 10.1017/s0022215100130117. View

15.

Chen A, Garcia J, Bucci M, Quivey J, Eisele D . Recurrent pleomorphic adenoma of the parotid gland: long-term outcome of patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006; 66(4):1031-5. DOI: 10.1016/j.ijrobp.2006.06.036. View

16.

Wittekindt C, Streubel K, Arnold G, Stennert E, Guntinas-Lichius O . Recurrent pleomorphic adenoma of the parotid gland: analysis of 108 consecutive patients. Head Neck. 2007; 29(9):822-8. DOI: 10.1002/hed.20613. View

17.

Gidley P, Herrera S, Hanasono M, Yu P, Skoracki R, Roberts D . The impact of radiotherapy on facial nerve repair. Laryngoscope. 2010; 120(10):1985-9. DOI: 10.1002/lary.21048. View

18.

Hontanilla B, Qiu S, Marre D . Effect of postoperative brachytherapy and external beam radiotherapy on functional outcomes of immediate facial nerve repair after radical parotidectomy. Head Neck. 2013; 36(1):113-9. DOI: 10.1002/hed.23276. View

19.

Makeieff M, Pelliccia P, Letois F, Mercier G, Arnaud S, Cesar C . Recurrent pleomorphic adenoma: results of surgical treatment. Ann Surg Oncol. 2010; 17(12):3308-13. DOI: 10.1245/s10434-010-1173-2. View

20.

Portelinha J, Passarinho M, Costa J . Neuro-ophthalmological approach to facial nerve palsy. Saudi J Ophthalmol. 2015; 29(1):39-47. PMC: 4314567. DOI: 10.1016/j.sjopt.2014.09.009. View